HEIDELBERG
UNIVERSITY
HOSPITAL

SCIENTIFIC PROGRAM

10TH HEIDELBERG MYELOMA WORKSHOP

Congress venue:
Event location „Frauenbad“
Bergheimer Straße 45 | 69115 Heidelberg
(inside the „Altes Hallenbad“)

FRIDAY, APRIL 25TH, 2025

SATURDAY, APRIL 26TH, 2025

NCT
NATIONALES CENTRUM
FÜR TUMORERKRANKUNGEN
HEIDELBERG
Deutsches Krebsforschungszentrum
Universitätsklinikum Heidelberg
Universität Heidelberg
Thoraxklinik Heidelberg

UK
HD

DEAR COLLEAGUES,

Welcome to the 10th Heidelberg Myeloma Workshop!

This biennial meeting continues to highlight the latest advancements in multiple myeloma research and therapy, with internationally renowned experts sharing cutting-edge insights into the disease's pathogenesis and the latest therapeutic strategies.

Recent years have brought significant progress, with myeloma patients benefiting from refined diagnostic criteria and innovative treatments. Earlier treatment initiation and a focus on achieving sustained deep remissions have opened new avenues to improve patient outcomes. Notably, the approval of novel agents and the rise of immunotherapies, such as T-cell engagers and CAR-T cells, have transformed the treatment landscape.

Recognizing myeloma as a spectrum of diseases, we now have the tools to adopt a more tailored approach. Advances in molecular profiling of both the tumor and its microenvironment, coupled with deeper insights into clinical parameters, allow for more precise risk stratification. These developments support emerging risk-adapted treatment strategies. Promising early results from these efforts will be shared during the meeting.

We hope you find the program thought-provoking and insightful.

The official language of the meeting is English.

Sincerely,

Prof. Dr. Marc S. Raab

PD Dr. Niels Weinhhold

FRIDAY, APRIL 25TH, 2025

12.00 – 12.45 p.m. Registration and Get Together

12.45 – 1.00 p.m. Introduction and Opening Remarks
Carsten Müller-Tidow, Marc-Steffen Raab, Niels Weinhold

SESSION I 1.00 – 2.00 p.m.
Plasma Cell Biology

1.00 – 1.10 p.m.
Single cell high risk myeloma
Brian Walker

1.10 – 1.20 p.m.
Lessons learned from sequencing studies
Gareth Morgan

1.20 – 1.30 p.m.
Biologic insights from proteomics studies
Jan Krönke

1.30 – 1.40 p.m.
Role of normal plasma cells
Niccolo Bolli

1.40 – 2.00 p.m.
Summary and Discussion
Dirk Hose

2.00 – 3.00 p.m.
Key Note Lecture

2.00 – 2.30 p.m.
A Post-Data World: Linking Context, Data, and Biomedical Literature with LLMs
Garry Nolan

2.30 – 2.40 p.m.
Cellular compartments and neighborhoods
Marc-Andrea Bärtsch

2.40 – 3.00 p.m.
Summary and Discussion
Tom Cupedo

3.00 – 3.30 p.m.
Coffee Break

SESSION II 3.30 – 4.50 p.m.
First-line therapy

3.30 – 3.40 p.m.
Strategies in SMM
Sagar Lonial

3.40 – 3.50 p.m.
First-line non transplant
Philippe Moreau

3.50 – 4.00 p.m.
First-line transplant
Shaji Kumar

4.00 – 4.10 p.m.
Post transplant maintenance
Elias K. Mai

4.10 – 4.20 p.m.
Disparities in Health Care Systems: First-line therapy in South Korea
Ji Hyun Lee

4.20 – 4.50 p.m.
Summary and Discussion
Katja Weisel

4.50 – 5.20 p.m.
Coffee Break

SESSION III 5.20 – 6.30 p.m.

Risk-adapted and targeted therapies

5.20 – 5.30 p.m.
How to define and treat high-risk myeloma
Martin Kaiser

5.30 – 5.40 p.m.
Prediction models
Francesco Maura

5.40 – 5.50 p.m.
Novel therapy in pre-clinical models
Marta Chesi

5.50 – 6.00 p.m.
The potential of immunotherapies to overcome high-risk
Leo Rasche

6.00 – 6.30 p.m.
Summary and Discussion
Hartmut Goldschmidt

6.30 – 6.40 p.m.

Short summary and end of first day

SATURDAY, APRIL 26TH, 2025

9.00 – 9.30 a.m. Get Together

SESSION I 9.30 – 10.40 a.m.
Cellular therapies

9.30 – 9.40 a.m.
RWE on CARs
Kai Rejeski

9.40 – 9.50 a.m.
CARs in earlier lines
Saad Usmani

9.50 – 10.00 a.m.
Liquid Biopsy and Next-Gen Immunotherapies
Jens Lohr

10.00 – 10.10 a.m.
Monitoring response to CARs using imaging
Jens Hillengass

10.10 – 10.40 a.m.
Summary and Discussion
Raphael Teipel

10.40 – 11.00 a.m.
Coffee Break

SESSION II 11.00 a.m – 12.10 p.m.
Immunotherapy

11.00 – 11.10 a.m.
Antibody-drug conjugates
Suzanne Trudel

11.10 – 11.20 a.m.
BCMA-targeting bispecific antibodies
Salomon Manier

11.20 – 11.30 a.m.
Non-BCMA immunotherapies
Nizar Bahlis

11.30 – 11.40 a.m.
MRD and immunotherapies
Bruno Paiva

11.40 a.m. – 12.10 p.m.
Summary and Discussion
Hans Salwender

12.10 – 1.15 p.m.
Lunch

SESSION III 1.15 – 2.35 p.m.
Microenvironment

1.15 – 1.25 p.m.
Resistance to T cell-based therapies
Paola Neri

1.25 – 1.35 p.m.
Non T-cell compartment in bone marrow
Tom Cupedo

1.35 – 1.45 p.m.
Immunosurveillance in myeloma
Mirco Friedrich

1.45 – 1.55 p.m.
Co-evolution of cancer and immune cell trajectories in multiple myeloma
Simon Haas

1.55 – 2.05 p.m.
Future single-cell technologies to study the tumor-microenvironment
Ido Amit

2.05 – 2.35 p.m.
Summary and Discussion
Leo Rasche

2.35 – 3.00 p.m.
Coffee Break

SESSION IV 3.00 – 4.10 p.m.
Current and future approaches in rrMM

3.00 – 3.10 p.m.
Melflufen and CRBN
Paul Richardson

3.10 – 3.20 p.m.
XPO1 and other targets (BCL-2, NSD-2)
Leif Bergsagel

3.20 – 3.30 p.m.
NK-cell mediated strategies
Mark Bustoros

3.30 – 3.40 p.m.
Next Generation CARs
Hermann Einsele

3.40 – 4.10 p.m.
Summary and Discussion
Cyrus Khandanpour

4.10 – 4.15 p.m.
Summary and end of the workshop

SPEAKERS AND DISCUSSANTS

Ido Amit, PhD, Rehovot, Israel
Marc-Andrea Bärtsch, MD, Heidelberg, Germany
Nizar Bahlis, MD, Calgary, Canada
Leif Bergsagel, MD, Scottsdale, AZ, USA
Niccolo Bolli, MD, PhD, Milano, Italy
Mark Bustoros, MD, New York, NY, USA
Marta Chesi, PhD, Scottsdale, AZ, USA
Tom Cupedo, PhD, Rotterdam, Netherlands
Hermann Einsele, MD, Würzburg, Germany
Mirco J. Friedrich, MD, PhD, Heidelberg, Germany
Hartmut Goldschmidt, MD, Heidelberg, Germany
Simon Haas, MD, Berlin, Germany
Jens Hillengass, MD, PhD, Buffalo, NY, USA
Dirk Hose, MD, Pfäffikon, Switzerland
Martin Kaiser, MD, London, UK
Cyrus Khandanpour, MD, Lübeck, Germany
Jan Krönke, MD, Greifswald, Germany
Shaji K. Kumar, MD, Rochester, NY, USA
Ji Hyun Lee, MD, PhD, Busan, Korea
Jens G. Lohr, MD, PhD, Salt Lake City, UT, USA
Sagar Lonial, MD, FACP, Atlanta, GA, USA
Elias K. Mai, MD, Heidelberg, Germany
Salomon Manier, MD, Lille, France
Francesco Maura, MD, New York, NY, USA
Philippe Moreau, MD, Nantes, France
Gareth Morgan, MD, PhD, New York, NY, USA
E. Paola Neri, MD, PhD, Calgary, Canada
Garry Nolan, MD, Stanford, CA, USA
Bruno Paiva, MD, PhD, Pamplona, Spain
Leo Rasche, MD, Würzburg, Germany
Kai Rejeski, MD, Munich, Germany
Paul Richardson, MD, Boston, MA, USA
Hans Salwender, MD, Hamburg, Germany
Raphael Teipel, MD, Dresden, Germany
Suzanne Trudel, MD, FRCPC, Toronto, Canada
Saad Usmani, MD, MBA, FACP, FASCO, New York, NY, USA
Brian Walker, PhD, Miami, FL, USA
Katja Weisel, MD, Hamburg, Germany

We would like to thank all our sponsors for supporting the 10th Heidelberg Myeloma Workshop:

AbbVie Deutschland GmbH & Co.KG
65189 Wiesbaden – 15.000€

Amgen GmbH
80992 München – 15.000€

Bristol-Myers Squibb GmbH & Co. KGaA
80636 München – 30.000€

GlaxoSmithKline GmbH & Co. KG
81675 München – 30.000€

Janssen-Cilag GmbH
41470 Neuss – 40.000€

Oncopeptides GmbH
81541 München – 2.500€

Pfizer Pharma GmbH
10785 Berlin – 15.000€

Regeneron Deutschland
80336 München – 15.000€

Sanofi-Aventis Deutschland GmbH
65926 Frankfurt – 30.000€

Sebia Labordiagnostische Systeme GmbH
55129 Mainz – 1.200€

Menarini Stemline Deutschland GmbH
12489 Berlin – 15.000€

The Binding Site GmbH
68723 Schwetzingen – 2.000€

Sponsors will receive the opportunity to advertise their products before and/or after the event.

ORGANISATION AND CONGRESS VENUE

10TH HEIDELBERG MYELOMA WORKSHOP

University Hospital Heidelberg
Department of Medicine V and
National Center for Tumor Diseases (NCT)
Multiple Myeloma Section
Im Neuenheimer Feld 410 | 69120 Heidelberg

CONGRESS VENUE

Event location „Frauenbad“
Bergheimer Straße 45 | 69115 Heidelberg
(inside the „Altes Hallenbad“)

CONTACT AND REGISTRATION

Laura Schaaf
Phone: **+49 6221 56-8009**
E-Mail: **laura.schaaf@med.uni-heidelberg.de**

Register online at:
https://www.myelomaworkshop.de/

WWW.KLINIKUM.UNI-HEIDELBERG.DE
WWW.NCT-HEIDELBERG.DE